BMY
Who in Congress traded BMY, when, and what happened after?
A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.
Party Breakdown
Party Trading Divergence
Democrat vs. Republican buy / sell pressure by monthHIGH DIVERGENCEBar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.
🏛️ Federal Contracts
all →- 2026-06-16$364KDepartment of Veterans AffairsBREYANZI CAR T - TRANSPLANT
- 2026-06-16$364KDepartment of Veterans AffairsBREYANZI CAR T
- 2026-06-11$17KDepartment of Veterans AffairsPOMALYST 2 MG
- 2026-06-02$364KDepartment of Veterans AffairsBREAYNAZI FOR CAR-T TRANSPLANT MEDICATION
- 2026-05-29$149KDepartment of Veterans AffairsPOMALYST 2 MG, 3 MG,4 MG
- 2026-05-29$12KDepartment of Veterans AffairsPATIENT MEDICATION - THALIDOMIDE 100MG - SHIP TO BALTIMORE VA MEDICAL CENTER PHARMACY.
- 2026-05-27$11KDepartment of Veterans AffairsPOMALYST 3 MG
- 2026-05-21$16KDepartment of Veterans AffairsPOMALIDOMIDE(POMALYST) 4MG CAP
- 2026-05-21$16KDepartment of Veterans AffairsPOMALYST 4 MG
- 2026-05-14$364KDepartment of Veterans AffairsBREYANZI CAR-T
💼 Lobbying Filings
all →- 2026-04-20$1.3MBRISTOL-MYERS SQUIBB COMPANYH.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues
- 2026-04-20$80KBRISTOL-MYERS SQUIBB COMPANY340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
- 2026-04-20$80KBRISTOL-MYERS SQUIBBPolicies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
- 2026-04-20$60KBRISTOL-MYERS SQUIBBValue of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D, MFN U.S. Competitiveness issues
- 2026-04-20$60KBRISTOL-MYERS SQUIBB COMPANYIssues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process
- 2026-04-20$50KBRISTOL-MYERS SQUIBB COMPANYBiosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
- 2026-04-20$40KBRISTOL-MYERS SQUIBBIssues regarding approved and pipeline products, and related policy. 340 program issues. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy.
- 2026-04-20$30KBRISTOL-MYERS SQUIBB COMPANYEducation about the value of biopharmaceutical innovation and related issues.
- 2026-04-20$0BRISTOL-MYERS SQUIBB COMPANYIssues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.
- 2026-04-19$0BRISTOL-MYERS SQUIBB
Congressional Momentum
buy vs. sell pressureDISTRIBUTINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Best Timers
avg excess return vs SPY · BMY trades only10 members w/ alpha dataExcess return = stock price change minus SPY change over the same holding window.Congress avg: -8.5%· 20% of traders beat SPY on this name
Timing Fingerprint
filing delay vs. excess return over SPY · 39 tradesCongress avg -1.7% vs SPYEach dot = one disclosed trade. X-axis = days between trade and STOCK Act filing.Y-axis = return above (or below) SPY over the subsequent holding window. Upper-right = late filers who beat the market.
Congress Swarm Events
synchronized trading — 3+ members within 21 daysSUSPICIOUSA swarm event occurs when 3 or more members disclose trades in BMY within a rolling 21-day window. Tight windows with high directional consensus score highest on the suspicion meter.
Trade Activity Timeline
Congressional buys & sells by month · last 24 months w/ activity
Who Moved First
each row = one member · sorted by earliest disclosed tradeSeasonal Rhythm
Congress buy/sell pressure by month & yearEach cell = one calendar month. Green = net Congress buying, red = net selling. Intensity ∝ consensus strength. Hover for details.
Congressional Conviction Timeline
net positioning · alpha track recordBEARISHAll Disclosed Trades
| Date | Member | Action | Amount | Filing Delay | Receipt |
|---|---|---|---|---|---|
| 2026-05-07 | RMike Kelly | SELL | $15K – $50K | 36d | receipt → |
| 2026-05-07 | RMike Kelly | SELL | $15K – $50K | 35d | receipt → |
| 2026-05-15 | DRo Khanna | BUY | $1K – $15K | 25d | receipt → |
| 2026-04-13 | DRo Khanna | BUY | $1K – $15K | 28d | receipt → |
| 2026-02-05 | DRo Khanna | BUY | $1K – $15K | 32d | receipt → |
| 2026-01-29 | DRo Khanna | SELL | $15K – $50K | 8d | receipt → |
| 2026-01-23 | DRo Khanna | BUY | $1K – $15K | 14d | receipt → |
| 2025-12-18 | DJulie Johnson | SELL | $1K – $15K | 29d | receipt → |
| 2025-12-18 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-04-28 | RJulia Letlow | SELL | $1K – $15K | 261d | receipt → |
| 2025-12-19 | DGilbert Cisneros | BUY | $1K – $15K | 25d | receipt → |
| 2025-04-28 | RJulia Letlow | SELL | $1K – $15K | 260d | receipt → |
| 2024-10-23 | RJulia Letlow | BUY | $1K – $15K | 447d | receipt → |
| 2025-12-19 | DGilbert Cisneros | BUY | $1K – $15K | 24d | receipt → |
| 2025-11-12 | DGilbert Cisneros | BUY | $1K – $15K | 34d | receipt → |
| 2025-11-12 | DGilbert Cisneros | BUY | $1K – $15K | 33d | receipt → |
| 2025-11-13 | DJulie Johnson | SELL | $1K – $15K | 29d | receipt → |
| 2025-11-13 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-11-03 | DRo Khanna | BUY | $1K – $15K | 35d | receipt → |
| 2025-10-09 | DGilbert Cisneros | SELL | $1K – $15K | 41d | receipt → |
| 2025-10-09 | DGilbert Cisneros | SELL | $1K – $15K | 40d | receipt → |
| 2025-09-29 | DRo Khanna | SELL | $1K – $15K | 4d | receipt → |
| 2025-09-05 | DRo Khanna | BUY | $1K – $15K | 28d | receipt → |
| 2025-08-14 | DJulie Johnson | SELL | $1K – $15K | 29d | receipt → |
| 2024-10-29 | DValerie Hoyle | BUY | $1K – $15K | 318d | receipt → |
| 2025-08-14 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-08-04 | DRo Khanna | SELL | $1K – $15K | 36d | receipt → |
| 2025-06-23 | DRo Khanna | BUY | $1K – $15K | 16d | receipt → |
| 2025-06-24 | RVirginia Foxx | SELL | $1K – $15K | 10d | receipt → |
| 2025-06-24 | RVirginia Foxx | SELL | $1K – $15K | 9d | receipt → |
| 2025-06-24 | RVirginia Foxx | SELL | $1K – $15K | 7d | receipt → |
| 2025-06-24 | RVirginia Foxx | SELL | $1K – $15K | 7d | receipt → |
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 42d | receipt → |
| 2025-05-19 | DRo Khanna | SELL | $1K – $15K | 22d | receipt → |
| 2025-04-15 | RTommy Tuberville | SELL | $1K – $15K | 31d | receipt → |
| 2025-04-15 | RTommy Tuberville | SELL | $1K – $15K | 30d | receipt → |
| 2025-04-01 | DJulie Johnson | SELL | $1K – $15K | 43d | receipt → |
| 2025-03-27 | DGreg Landsman | SELL | $1K – $15K | 12d | receipt → |
| 2025-01-15 | DJulie Johnson | BUY | $1K – $15K | 28d | receipt → |
| 2024-12-06 | RVirginia Foxx | BUY | $1K – $15K | 31d | receipt → |
| 2024-12-06 | RVirginia Foxx | BUY | $1K – $15K | 31d | receipt → |
| 2024-02-22 | RByron Donalds | SELL | $1K – $15K | 260d | receipt → |
| 2024-08-05 | DRo Khanna | BUY | $1K – $15K | 32d | receipt → |
| 2024-07-02 | DRo Khanna | BUY | $1K – $15K | 36d | receipt → |
| 2024-07-01 | DRo Khanna | BUY | $1K – $15K | 37d | receipt → |
| 2024-05-29 | DRo Khanna | SELL | $15K – $50K | 7d | receipt → |
| 2024-05-28 | DRo Khanna | SELL | $15K – $50K | 8d | receipt → |
| 2024-04-03 | RTommy Tuberville | SELL | $1K – $15K | 42d | receipt → |
| 2024-04-03 | RTommy Tuberville | BUY | $1K – $15K | 42d | receipt → |
| 2024-04-03 | RTommy Tuberville | SELL | $1K – $15K | 42d | receipt → |
| 2024-04-26 | DRo Khanna | BUY | $1K – $15K | 10d | receipt → |
| 2024-02-13 | DRo Khanna | SELL | $1K – $15K | 22d | receipt → |
| 2024-02-13 | DRo Khanna | BUY | $15K – $50K | 22d | receipt → |
| 2024-01-03 | RTommy Tuberville | PARTIAL_SELL | $1K – $15K | 43d | receipt → |
| 2024-01-09 | DRick Larsen | SELL | $1K – $15K | 3d | receipt → |
| 2023-10-17 | RTommy Tuberville | BUY | $1K – $15K | 31d | receipt → |
| 2023-08-22 | RDan Sullivan | SELL | $1K – $15K | 27d | receipt → |
| 2023-05-10 | RShelley Capito | SELL | $1K – $15K | 110d | receipt → |
| 2023-01-10 | RDan Sullivan | PARTIAL_SELL | $1K – $15K | 230d | receipt → |
| 2022-06-17 | RShelley Capito | PARTIAL_SELL | $1K – $15K | 437d | receipt → |
| 2018-12-28 | DSheldon Whitehouse | SELL | $15K – $50K | 1704d | receipt → |
| 2020-11-25 | DRick Larsen | BUY | $1K – $15K | 904d | receipt → |